EGFR and breast cancer: Overexpression of RTKs such as EGFR, HER2, and IGF-1R promotes the downregulation of ERα and leads to resistance of ER+ BC to anti-estrogen therapy through activation of the PI3K/Akt and MAPK pathways [107,108].